Navigation Links
Sharp Edge Labs and SpectraGenetics Sign Agreement to Provide Better Assays for Studying G-Protein Coupled Receptors
Date:10/29/2013

PITTSBURGH, Oct. 29, 2013 /PRNewswire-iReach/ -- Sharp Edge Labs and SpectraGenetics, two Pittsburgh-based biotechnology companies, have entered into an Assay Development Agreement that will allow the companies to offer their industry leading assays for studying the detailed function of an important class of pharmaceutical targets, the G-Protein Coupled Receptors, or GPCRs.  GPCRs are the most common target of today's blockbuster drugs, including drugs for diseases ranging from hypertension and allergy to migraines, pain and cancer.  "While GPCRs are among the most-studied drug targets, we are just now learning important new aspects of how they work.  These assays provide unprecedented detail in understanding these new aspects of activity for the industry's most valuable drug targets" said Dr. Scott Sneddon, Ph.D., J.D., President and CEO of Sharp Edge Labs.  

(Photo: http://photos.prnewswire.com/prnh/20131029/MN04907)

"Working together, we can now offer a comprehensive set of tools for pharmaceutical and academic researchers including reagents and read-to-run assay kits, as well as assay services for profiling and screening compounds" added Dr. Reid Asbury, Ph.D., CEO of SpectraGenetics.  "Several large-pharma customers are already using the technology to study so-called 'ligand bias' or 'functional selectivity' of GPCRs.  By combining SpectraGenetics' catalog of over 150 GPCRs with Sharp Edge Labs' assay development expertise, we believe we can help researchers address any question in this important new field of drug research" he added.

SpectraGenetics provides research reagents to the pharma/biotech industry and academic labs.  SpectraGenetics has a large catalog of tagged genes, including a large selection of tagged GPCRs.   Sharp Edge Labs is the exclusive licensee of the Fluorogen Activating Peptide technology from CMU and provides assay products and services for pharma/biotech researchers in the areas of Receptors, Ion Channels and Transporters.  The company's web-sites are www.spectragenetics.com and www.sharpedgelabs.com.  Detailed images of the technology in use  suitable for print or web publication can be found at www.sharpedgelabs.com/media-images

Media Contact: Scott Sneddon, PhD, JD, Sharp Edge Labs, Inc., 412-475-9733, scott@sharpedgelabs.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Sharp Edge Labs, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Rehrig Pacific Company Receives FDA Approval for New Reusable Sharps Container
2. Sharp Rees-Stealy Medical Centers Launches Asthmapolis Mobile Asthma Management Program
3. Safe in Commons "The Unfinished Agenda: Addressing the Challenges" Crystalizes Call for Unified Protection Against Needlestick and Sharps Injuries
4. Brain Resource Featured as Market Leader in SharpBrains New Report on The State of the Digital Brain Health Market 2012-2020
5. Daniels Sharpsmart Canada Awarded HealthPro Contract And Appoints Daniel Kennedy CEO Of Daniels Canada
6. Circassia Appoints Stewart Sharpe as Vice President Commercial Operations
7. Study Confirms Daniels Sharpsmart Helps Hospitals Reduce Carbon Footprint
8. Philips and Infraredx sign agreement for the resale of Infraredxs TVC Imaging System integrated with Philips interventional X-ray systems
9. Valeant Pharmaceuticals Announces Settlement Agreement With Anacor
10. InCube Labs Enters into an Agreement with the Engineering Research Center for Revolutionizing Metallic Biomaterials
11. Bioject Enters Into Agreement With Fondaco PTE LTD For Distribution Of Full Line Of Needle Free Injection Devices In Asia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... HILL, N.C. , June 24, 2016 /PRNewswire/ ... healthcare decisions and regulators/payers have placed more emphasis ... new environment, patient support programs in the pharmaceutical ... for patients, medications. Consequently, pharmaceutical companies are focusing ... ensure they are providing products and services that ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... , June 24, 2016 ... Markets has announced the addition of the " ... offering. This ... and provides an updated review, including its applications in ... the total market, which includes three main industries: pharmaceutical ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
Breaking Medicine News(10 mins):